Back to today’s briefing

Story perspectives

Promising Results for New Typhoid Vaccine Trial

10/10/2025

36 3

Summary

Story summary

University of Maryland researchers completed Phase 1 trial of Trivalent Salmonella Conjugate Vaccine (TSCV) for typhoid and non-typhoidal Salmonella.
Twenty-two healthy adults received low or high dose or placebo, with safety and strong immune responses observed.
TSCV uses conjugate technology to boost immune recognition. Future studies will test efficacy in infants and children, and assess U.S. impact (1.35 million annually).

1 of 1

Story summary

University of Maryland researchers completed Phase 1 trial of Trivalent Salmonella Conjugate Vaccine (TSCV) for typhoid and non-typhoidal Salmonella.
Twenty-two healthy adults received low or high dose or placebo, with safety and strong immune responses observed.
TSCV uses conjugate technology to boost immune recognition. Future studies will test efficacy in infants and children, and assess U.S. impact (1.35 million annually).